Terns Pharmaceuticals, Inc.
TERN
$2.92
-$0.13-4.26%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 1.50% | -3.60% | -33.07% | -33.71% | -49.49% |
| Total Depreciation and Amortization | 1.70% | 0.89% | -0.65% | -8.30% | -14.63% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -33.74% | -36.96% | 86.18% | 90.46% | 82.05% |
| Change in Net Operating Assets | 197.02% | -128.25% | -174.70% | -212.56% | 242.24% |
| Cash from Operations | -3.90% | -26.08% | -51.84% | -51.04% | -37.23% |
| Capital Expenditure | 19.23% | -104.76% | -261.54% | -145.45% | 81.09% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 67.40% | 229.62% | 195.60% | -1,423.71% | -72.46% |
| Cash from Investing | 67.33% | 229.47% | 195.44% | -1,412.69% | -70.56% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 288.66% | 31.91% | -92.71% | -92.65% | -74.75% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -12.79% | 87.52% | 100.00% | 100.00% | 14.21% |
| Cash from Financing | 290.92% | 32.44% | -92.68% | -92.62% | -74.89% |
| Foreign Exchange rate Adjustments | -147.86% | 388.17% | 184.98% | 156.11% | 165.73% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 228.75% | 1,025.86% | -83.50% | -184.89% | -166.27% |